A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer

NCT03481920 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Stopped Enrollment

Conditions

Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer

Interventions

DRUG: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
DRUG: Avelumab

Sponsor

PH Research, S.L.